PMID- 36893559
OWN - NLM
STAT- MEDLINE
DCOM- 20230410
LR  - 20230412
IS  - 1476-5586 (Electronic)
IS  - 1522-8002 (Print)
IS  - 1476-5586 (Linking)
VI  - 39
DP  - 2023 May
TI  - Combined phospholipids adjuvant augments anti-tumor immune responses through 
      activated tumor-associated dendritic cells.
PG  - 100893
LID - S1476-5586(23)00018-0 [pii]
LID - 10.1016/j.neo.2023.100893 [doi]
LID - 100893
AB  - Dendritic cells (DCs) can initiate both naive and memory T cell activation, as 
      the most potent antigen-presenting cells. For efficient anti-tumor immunity, it 
      is essential to enhance the anti-tumoral activity of tumor-associated DCs (TADCs) 
      or to potently restrain TADCs so that they remain immuno-stimulating cells. 
      Combined phospholipids (cPLs) adjuvant may act through the activation of DCs. 
      This study demonstrated the potential mechanism of tumor growth inhibition of 
      cPLs adjuvant, and confirmed that cPLs adjuvant could induce the maturation and 
      activation (upregulation of MHC-II, CD80, CD40, IL-1beta, IL-12, IL-6 expression) of 
      BMDCs in vitro. Then we isolated tumor infiltrating lymphocytes (TILs) from solid 
      tumor and analyzed the phenotype and cytokines of TILs. The examination of the 
      TILs revealed that cPLs adjuvant upregulated the expression of co-stimulatory 
      molecules (MHC-II, CD86), phosphatidylserine (PS) receptor (TIM-4) on TADCs and 
      enhanced the cytotoxic effect (CD107a), as well as pro-inflammatory cytokine 
      production (IFN-gamma, TNF-alpha, IL-2) by the tumor-resident T cells. Taken together, 
      cPLs adjuvant may be an immune-potentiating adjuvant for cancer immunotherapy. 
      This reagent may lead to the development of new approaches in DC-targeted cancer 
      immunotherapy.
CI  - Copyright (c) 2023. Published by Elsevier Inc.
FAU - Shui, Yifang
AU  - Shui Y
AD  - Department of Hepatobiliary and Pancreatic Surgery, The First Affiliated Hospital 
      of Zhengzhou University, Zhengzhou, China; Division of Transplantation 
      Immunology, National Research Institute for Child Health and Development, Tokyo, 
      Japan.
FAU - Hu, Xin
AU  - Hu X
AD  - Division of Transplantation Immunology, National Research Institute for Child 
      Health and Development, Tokyo, Japan.
FAU - Hirano, Hiroshi
AU  - Hirano H
AD  - Division of Transplantation Immunology, National Research Institute for Child 
      Health and Development, Tokyo, Japan.
FAU - Tsukamoto, Hirotake
AU  - Tsukamoto H
AD  - Department of Immunology, Graduate School of Medical Sciences, Kumamoto 
      University, Kumamoto, Japan; Division of Clinical Immunology and Cancer 
      Immunotherapy, Center for Cancer Immunotherapy and Immunobiology, Graduate School 
      of Medicine, Kyoto University, Japan.
FAU - Guo, Wen-Zhi
AU  - Guo WZ
AD  - Department of Hepatobiliary and Pancreatic Surgery, The First Affiliated Hospital 
      of Zhengzhou University, Zhengzhou, China. Electronic address: 
      fccguowz@zzu.edu.cn.
FAU - Hasumi, Kenichiro
AU  - Hasumi K
AD  - Hasumi International Research Foundation, Tokyo, Japan.
FAU - Ijima, Fumihiro
AU  - Ijima F
AD  - Hasumi International Research Foundation, Tokyo, Japan. Electronic address: 
      ijima@shukokai.org.
FAU - Fujino, Masayuki
AU  - Fujino M
AD  - Division of Transplantation Immunology, National Research Institute for Child 
      Health and Development, Tokyo, Japan; Management Department of Biosafety, 
      Laboratory Animal, and Pathogen Bank, National Institute of Infectious Diseases, 
      Tokyo, Japan. Electronic address: mfujino-kkr@umin.ac.jp.
FAU - Li, Xiao-Kang
AU  - Li XK
AD  - Department of Hepatobiliary and Pancreatic Surgery, The First Affiliated Hospital 
      of Zhengzhou University, Zhengzhou, China; Division of Transplantation 
      Immunology, National Research Institute for Child Health and Development, Tokyo, 
      Japan. Electronic address: ri-k@ncchd.go.jp.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20230307
PL  - United States
TA  - Neoplasia
JT  - Neoplasia (New York, N.Y.)
JID - 100886622
RN  - 0 (Cytokines)
SB  - IM
MH  - Humans
MH  - *Dendritic Cells
MH  - *Neoplasms/therapy/metabolism
MH  - T-Lymphocytes
MH  - Cytokines/metabolism
MH  - Lymphocyte Activation
PMC - PMC10018555
OTO - NOTNLM
OT  - Cancer immunotherapy
OT  - Combined phospholipids
OT  - Tumor microenvironment
OT  - Tumor-associated dendritic cells
OT  - Tumor-infiltrating lymphocytes
COIS- Declaration of Competing Interest The authors declare the following financial 
      interests/personal relationships which may be considered as potential competing 
      interests: FI and KH are employees of Hasumi International Research Foundation
EDAT- 2023/03/10 06:00
MHDA- 2023/04/10 06:42
PMCR- 2023/03/07
CRDT- 2023/03/09 18:10
PHST- 2022/11/24 00:00 [received]
PHST- 2023/02/28 00:00 [accepted]
PHST- 2023/04/10 06:42 [medline]
PHST- 2023/03/10 06:00 [pubmed]
PHST- 2023/03/09 18:10 [entrez]
PHST- 2023/03/07 00:00 [pmc-release]
AID - S1476-5586(23)00018-0 [pii]
AID - 100893 [pii]
AID - 10.1016/j.neo.2023.100893 [doi]
PST - ppublish
SO  - Neoplasia. 2023 May;39:100893. doi: 10.1016/j.neo.2023.100893. Epub 2023 Mar 7.